Skip to main content

Multidisciplinary care in patients with prostate cancer: room for improvement

Supportive Care in Cancer volume 21, pages 2327–2333 (2013)Cite this article

Abstract

Purpose

New multimodality treatment approaches for prostate cancer require multidisciplinary management of patients. We aimed to assess the current practices of multidisciplinarity and their possible implications in treatment management in Switzerland.

Methods

In a survey, urologists and medical oncologists in Switzerland were asked to include at least 25 or 15 consecutive patients with the diagnosis of prostate cancer, respectively. Information about treatment patterns and multidisciplinary parameters of these patients was collected retrospectively.

Results

Thirty-seven urologists and 20 oncologists from the French- and German-speaking parts of Switzerland representing 7 out of 11 non-university tertiary centres and 20/10 % of all office-based urologists/oncologists in Switzerland collected data on 1,184 patients. Sixty-five percent of the office-based (16/24 urologists; 6/10 oncologists) and 95 % of the hospital-based (10/11 urologists; 8/8 oncologists) physicians participate in multidisciplinary tumour boards (MTBs). However, only 1.5 % of patients with a new diagnosis of prostate cancer (13 of 883) are discussed at a MTB. Overall, second opinions at diagnosis are requested in 23 % of patients, mainly from radiation oncologists (8.4 %) or fellow urologists (7.4 %). Second opinions are more often requested by urologists who participate at MTBs and in case of advanced stage.

Conclusions

Participation at MTBs is high among Swiss urologists and oncologists in private practice and at non-university tertiary centers. In spite of that only a small minority of patietns with prostate cancer are presented at MTBs.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Picard JC, Golshayan AR, Marshall DT, Opfermann KJ, Keane TE (2012) The multi-disciplinary management of high-risk prostate cancer. Urol Oncol 30:3–15

    PubMed  Article  Google Scholar 

  2. Lu-Yao GL, Albertsen PC, Moore DF et al (2009) Outcomes of localized prostate cancer following conservative management. JAMA 302:1202–1209

    PubMed  Article  CAS  Google Scholar 

  3. Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117–1123

    PubMed  Article  Google Scholar 

  4. Payne HA, Gillatt DA (2007) Differences and commonalities in the management of locally advanced prostate cancer: results from a survey of oncologists and urologists in the UK. BJU Int 99:545–553

    PubMed  Article  Google Scholar 

  5. Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71

    PubMed  Article  Google Scholar 

  6. Mottet N, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59:572–583

    PubMed  Article  Google Scholar 

  7. Cooperberg MR, Cowan J, Broering JM, Carroll PR (2008) High-risk prostate cancer in the United States, 1990–2007. World J Urol 26:211–218

    PubMed  Article  Google Scholar 

  8. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178:S14–S19

    PubMed  Article  Google Scholar 

  9. Cooperberg MR, Moul JW, Carroll PR (2005) The changing face of prostate cancer. J Clin Oncol 23:8146–8151

    PubMed  Article  Google Scholar 

  10. Jeldres C, Suardi N, Walz J et al (2008) Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men. Eur Urol 54:107–116

    PubMed  Article  Google Scholar 

  11. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    PubMed  Article  CAS  Google Scholar 

  12. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422

    PubMed  Article  CAS  Google Scholar 

  13. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154

    PubMed  Article  Google Scholar 

  14. de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005

    PubMed  Article  Google Scholar 

  15. Ruhstaller T, Roe H, Thurlimann B, Nicoll JJ (2006) The multidisciplinary meeting: an indispensable aid to communication between different specialities. Eur J Cancer 42:2459–2462

    PubMed  Article  Google Scholar 

  16. Ko C, Chaudhry S (2002) The need for a multidisciplinary approach to cancer care. J Surg Res 105:53

    PubMed  Article  Google Scholar 

  17. Boyle FM, Robinson E, Dunn SM, Heinrich PC (2005) Multidisciplinary care in cancer: the fellowship of the ring. J Clin Oncol 23:916–920

    PubMed  Article  Google Scholar 

  18. Valicenti RK, Gomella LG, El-Gabry EA et al (2000) The multidisciplinary clinic approach to prostate cancer counseling and treatment. Semin Urol Oncol 18:188–191

    PubMed  CAS  Google Scholar 

  19. Gomella LG, Lin J, Hoffman-Censits J et al (2010) Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience. J Oncol Pract 6:e5–e10

    PubMed  Article  Google Scholar 

  20. Valdagni R, Albers P, Bangma C et al (2011) The requirements of a specialist prostate cancer unit: a discussion paper from the European School of Oncology. Eur J Cancer 47:1–7

    PubMed  Article  Google Scholar 

  21. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131

    PubMed  Article  Google Scholar 

  22. Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M (2010) Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 58:831–835

    PubMed  Article  Google Scholar 

  23. Bolla M, de Reijke TM, Van Tienhoven G et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360:2516–2527

    PubMed  Article  CAS  Google Scholar 

  24. Ganswindt U, Stenzl A, Bamberg M, Belka C (2008) Adjuvant radiotherapy for patients with locally advanced prostate cancer—a new standard? Eur Urol 54:528–542

    PubMed  Article  Google Scholar 

  25. Kibel AS (2005) An interdisciplinary approach to treating prostate cancer. Urology 65(6 Suppl):13–18

    PubMed  Article  Google Scholar 

  26. Hamilton AS, Albertsen PC, Johnson TK et al (2011) Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int 107:576–584

    PubMed  Article  Google Scholar 

  27. Cooperberg MR, Broering JM, Litwin MS et al (2004) The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 171:1393–1401

    PubMed  Article  Google Scholar 

  28. Aizer AA, Paly JJ, Zietman AL et al (2012) Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol 30:3071–3076

    PubMed  Article  Google Scholar 

Download references

Acknowledgments

This study was supported by an unrestricted grant from Sanofi-Aventis (Suisse) SA, Meyrin, Switzerland.

Conflict of interest

Richard Cathomas has a consultant role for Janssen Cilag and Sanofi-Aventis. Silke Gillessen has a consultant role for Novartis, Janssen Cilag, Pfizer, Sanofi-Aventis, GSK, and Millennium. All other authors report no conflicts of interest. We hereby state that we have full control of all data and we allow the journal to review the data if deemed necessary.

Author information

Affiliations

  1. Department of Urology, Kantonsspital Graubünden, Chur, Switzerland

    Räto T. Strebel

  2. Department of Urology, University Hospital Zurich, Zurich, Switzerland

    Tullio Sulser

  3. Department of Urology, Kantonsspital St. Gallen, St. Gallen, Switzerland

    Hans-Peter Schmid

  4. Department of Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland

    Silke Gillessen

  5. Department of Oncology, Southampton University Hospital, Southampton, UK

    Martin Fehr

  6. Medical Oncology, Klinik im Park, Zurich, Switzerland

    Urs Huber

  7. Department of Oncology, Kantonsspital Winterthur, Winterthur, Switzerland

    Miklos Pless

  8. Tumor Center ZeTuP, St. Gallen, Switzerland

    Rudolf Morant

  9. Department of Oncology, Kantonsspital Luzern, Luzern, Switzerland

    Ralph Winterhalder

  10. Department of Medical Oncology, Kantonsspital Graubünden, Loëstrasse 170, 7000, Chur, Switzerland

    Richard Cathomas

Authors
  1. Räto T. Strebel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tullio Sulser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hans-Peter Schmid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Silke Gillessen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martin Fehr
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Urs Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Miklos Pless
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rudolf Morant
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ralph Winterhalder
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Richard Cathomas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Cathomas.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Strebel, R.T., Sulser, T., Schmid, HP. et al. Multidisciplinary care in patients with prostate cancer: room for improvement. Support Care Cancer 21, 2327–2333 (2013). https://doi.org/10.1007/s00520-013-1791-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-013-1791-x

Keywords

  • Disease management
  • Health care survey
  • Interdisciplinary communication
  • Prostate cancer